AC
CNST

Athanor Capital’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Athanor Capital’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,473
Closed -$359K – 1110
2020
Q4 		$359K Buy
+12,473
New +$314K 0.01% 536
2020
Q3 		– Sell
-11,923
Closed -$358K – 717
2020
Q2 		$358K Buy
+11,923
New +$429K 0.02% 371
2020
Q1 		– Sell
-8,901
Closed -$419K – 413
2019
Q4 		$419K Buy
+8,901
New +$257K 0.02% 268

Other funds holding CNST

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Athanor Capital's CNST Position: Q1 2021 in Review

Athanor Capital sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q1 2021, closing a stake of 12,473 shares — an estimated $359K sold.

Athanor Capital first reported a position in CNST in Q4 2019 and held it in 3 quarters. The position peaked at $419K in Q4 2019. 131 funds tracked by Wall St. Rank hold CNST as of Q1 2021.

  • Athanor Capital reported no remaining Constellation Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Athanor Capital sold 12,473 Constellation Pharmaceuticals, Inc. shares in Q1 2021, an estimated $359K.
  • Athanor Capital first reported a position in Constellation Pharmaceuticals, Inc. in Q4 2019 and held it in 3 quarters.
  • Athanor Capital's Constellation Pharmaceuticals, Inc. position peaked at $419K in Q4 2019.
  • 131 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.